Adaptimmune Therapeutics plc (ADAPY)
OTCMKTS · Delayed Price · Currency is USD
0.0261
-0.0039 (-13.00%)
Jul 31, 2026, 11:52 AM EST
Adaptimmune Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 29.76 | -77.92 | -130.81 | -165.46 | -187.12 |
Depreciation & Amortization | 11.3 | 15.99 | 9.68 | 6.08 | 6.57 |
Stock-Based Compensation | -1.16 | 10.92 | 13.35 | 18.24 | 19.91 |
Other Adjustments | -121.98 | 49.7 | -29.83 | 0.9 | 23.57 |
Change in Receivables | -14.03 | -4 | 14.1 | -9.81 | -0.5 |
Changes in Inventories | -3.68 | -7.36 | - | - | - |
Changes in Accounts Payable | -9.54 | 9.94 | -3.51 | - | 6.87 |
Changes in Accrued Expenses | - | - | - | 4.41 | - |
Changes in Unearned Revenue | -6.68 | -69.8 | -14.57 | 3.87 | 149.79 |
Changes in Other Operating Activities | -0.16 | 0.3 | 1.5 | - | -13.15 |
Operating Cash Flow | -121.91 | -69.12 | -137.27 | -141.77 | 13.69 |
Operating Cash Flow Growth | - | - | - | - | - |
Investing Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -0.39 | -0.89 | -4.68 | -29.5 | -8.57 |
Sale of Property, Plant & Equipment | 50.58 | - | - | - | - |
Purchases of Intangible Assets | - | -1.02 | -0.02 | -0.24 | -0.71 |
Purchases of Investments | -16.09 | -100.42 | -75.95 | -48.12 | -139.76 |
Proceeds from Sale of Investments | 76.95 | 44.06 | 210.98 | 166.99 | 224.34 |
Cash Acquisitions | - | - | 43.61 | - | - |
Other Investing Activities | 0.22 | 1.09 | 1.55 | - | 2.88 |
Investing Cash Flow | 111.27 | -57.18 | 175.49 | 89.14 | 78.18 |
Financing Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Issued | - | 49.5 | - | - | - |
Long-Term Debt Repaid | -50.95 | - | - | - | - |
Net Long-Term Debt Issued (Repaid) | -50.95 | 49.5 | - | - | - |
Issuance of Common Stock | 1.84 | 29.25 | 0.88 | 12.87 | 3.29 |
Net Common Stock Issued (Repurchased) | 1.84 | 29.25 | 0.88 | 12.87 | 3.29 |
Other Financing Activities | -4.61 | -4.91 | -4.02 | - | -2.47 |
Financing Cash Flow | -53.72 | 73.84 | -3.14 | 12.87 | 0.82 |
Net Cash Flow
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | -0.83 | -0.4 | 0.88 | -2.3 | 0.38 |
Net Cash Flow | -64.36 | -52.45 | 35.08 | -42.06 | 92.69 |
Free Cash Flow
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -122.3 | -70 | -141.95 | -171.27 | 5.12 |
Free Cash Flow Growth | - | - | - | - | - |
FCF Margin | -2064.40% | - | -235.49% | -630.86% | 83.20% |
Free Cash Flow Per Share | -0.07 | -0.04 | -0.12 | -0.18 | 0.01 |
Levered Free Cash Flow | -34.87 | -80.22 | -156.11 | -180.6 | -16.6 |
Unlevered Free Cash Flow | -86.82 | -230.12 | -187.99 | -176.59 | -19.94 |